4.7 Review

Current status of intratumour microbiome in cancer and engineered exogenous microbiota as a promising therapeutic strategy

期刊

BIOMEDICINE & PHARMACOTHERAPY
卷 145, 期 -, 页码 -

出版社

ELSEVIER FRANCE-EDITIONS SCIENTIFIQUES MEDICALES ELSEVIER
DOI: 10.1016/j.biopha.2021.112443

关键词

Intratumoral bacteria; Genetically engineered bacteria; Tumor; Therapy

资金

  1. National Key Research and Development Program of China [2021YFA0910700, 2018YFA0902701]
  2. Guangdong Science and Technology Department [2020B1212030004]
  3. L & T Charitable Foundation
  4. Program for Guangdong Introducing Innovative and Entrepreneurial Teams [2019BT02Y198]
  5. Guangdong Basic and Applied Basic Research Foundation [2020A1515010038]
  6. Pearl River Science and Technology Nova Program of Guangzhou [201710010047]
  7. Presidential Foundation of Zhujiang Hospital of Southern Medical University [yzjj2018rc03]
  8. Hong Kong Scholars Program [XJ2016055]

向作者/读者索取更多资源

Research on the relationship between microbiome and cancer has advanced significantly, revealing the impact of gut microbiome and intratumoral bacteria on tumour biology. Studies have shown that intratumoral bacteria play a role in tumour initiation, progression, and response to treatment, presenting a potential avenue for cancer therapy. Despite the progress, challenges remain in utilizing genetically engineered bacteria for cancer treatment.
Research on the relationship between microbiome and cancer has made significant progress in the past few decades. It is now known that the gut microbiome has multiple effects on tumour biology. However, the relationship between intratumoral bacteria and cancers remains unclear. Growing evidence suggests that intratumoral bacteria are important components of the microenvironment in several types of cancers. Furthermore, several studies have demonstrated that intratumoral bacteria may directly influence tumorigenesis, progression and responses to treatment. Limited studies have been conducted on intratumoral bacteria, and using intratumoral bacteria to treat tumours remains a challenge. Bacteria have been studied as anticancer therapeutics since the 19th century when William B. Coley successfully treated patients with inoperable sarcomas using Streptococcus pyogenes. With the development of synthetic biological approaches, several bacterial species have been genetically engineered to increase their applicability for cancer treatment. Genetically engineered bacteria for cancer therapy have unique properties compared to other treatment methods. They can specifically accumulate within tumours and inhibit cancer growth. In addition, genetically engineered bacteria may be used as a vector to deliver antitumour agents or combined with radiation and chemotherapy to synergise the effectiveness of cancer treatment. However, various problems in treating tumours with genetically engineered bacteria need to be addressed. In this review, we focus on the role of intratumoral bacteria on tumour initiation, progression and responses to chemotherapy or immunotherapy. Moreover, we summarised the recent progress in the treatment of tumours with genetically engineered bacteria.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.7
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据